Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease

@article{Mller2006PharmacokineticBO,
  title={Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease},
  author={T. M{\"u}ller and C. Erdmann and S. Muhlack and D. Bremen and H. Przuntek and O. Goetze and D. Woitalla},
  journal={Journal of Neural Transmission},
  year={2006},
  volume={113},
  pages={1441-1448}
}
Summary.Addition of the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) prolongs plasma metabolism of levodopa (LD). Objectives were to determine the clinical response after EN addition and the plasma degradation of LD and 3-O-methyldopa [3-OMD]. Not optimum treated hospitalised patients with Parkinson’s disease received the same LD dosage on the first day only with carbidopa (CD) and on the second day with CD and EN (t.i.d.) within a standardised setting. We scored motor symptoms… Expand
Catechol-O-methyltransferase Inhibition Improves Levodopa-Associated Strength Increase in Patients With Parkinson Disease
Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
  • T. Müller
  • Medicine
  • Patient preference and adherence
  • 2009
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson’s disease
Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association.
Effects of chronic levodopa therapy on dopa pharmacokinetics.
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Levodopa and the progression of Parkinson's disease.
Gastric emptying in healthy volunteers after multiple doses of levodopa.
Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone
...
1
2
3
...